These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 30036625

  • 21. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [Abstract] [Full Text] [Related]

  • 22. Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.
    Wang A, Pei J, Shuai W, Lin C, Feng L, Wang Y, Lin F, Ouyang L, Wang G.
    J Med Chem; 2021 Nov 25; 64(22):16328-16348. PubMed ID: 34735773
    [Abstract] [Full Text] [Related]

  • 23. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
    Malkomes P, Lunger I, Luetticke A, Oppermann E, Haetscher N, Serve H, Holzer K, Bechstein WO, Rieger MA.
    Ann Surg Oncol; 2016 Sep 25; 23(9):2849-57. PubMed ID: 27059026
    [Abstract] [Full Text] [Related]

  • 24. Identification and characterization of RET fusions in advanced colorectal cancer.
    Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK.
    Oncotarget; 2015 Oct 06; 6(30):28929-37. PubMed ID: 26078337
    [Abstract] [Full Text] [Related]

  • 25. Integrating proteomics and transcriptomics for the identification of potential targets in early colorectal cancer.
    Yang W, Shi J, Zhou Y, Liu T, Zhan F, Zhang K, Liu N.
    Int J Oncol; 2019 Aug 06; 55(2):439-450. PubMed ID: 31268166
    [Abstract] [Full Text] [Related]

  • 26. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
    Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z, Koeffler HP, Yin D.
    PLoS One; 2016 Aug 06; 11(8):e0159954. PubMed ID: 27532268
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A, Aliper A, Korzinkin M, Lezhnina K, Jellen L, Zhukov N, Roumiantsev S, Gaifullin N, Zhavoronkov A, Borisov N, Buzdin A.
    Oncotarget; 2015 Oct 06; 6(30):29347-56. PubMed ID: 26320181
    [Abstract] [Full Text] [Related]

  • 30. The role of the PI3K pathway in colorectal cancer.
    Papadatos-Pastos D, Rabbie R, Ross P, Sarker D.
    Crit Rev Oncol Hematol; 2015 Apr 06; 94(1):18-30. PubMed ID: 25591826
    [Abstract] [Full Text] [Related]

  • 31. Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs.
    Gao B, Shao Q, Choudhry H, Marcus V, Dong K, Ragoussis J, Gao ZH.
    Int J Oncol; 2016 Sep 06; 49(3):1108-18. PubMed ID: 27571956
    [Abstract] [Full Text] [Related]

  • 32. Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing.
    Li Z, Powell CE, Groendyke BJ, Gero TW, Feru F, Feutrill J, Chen B, Li B, Szabo H, Gray NS, Scott DA.
    Bioorg Med Chem Lett; 2020 Oct 01; 30(19):127456. PubMed ID: 32739400
    [Abstract] [Full Text] [Related]

  • 33. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
    Dienstmann R, Tabernero J.
    Cancer J; 2016 Oct 01; 22(3):149-55. PubMed ID: 27341591
    [Abstract] [Full Text] [Related]

  • 34. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 35. Protein kinase, membrane‑associated tyrosine/threonine 1 is associated with the progression of colorectal cancer.
    Jeong D, Kim H, Kim D, Ban S, Oh S, Ji S, Kang D, Lee H, Ahn TS, Kim HJ, Bae SB, Lee MS, Kim CJ, Kwon HY, Baek MJ.
    Oncol Rep; 2018 Jun 10; 39(6):2829-2836. PubMed ID: 29658598
    [Abstract] [Full Text] [Related]

  • 36. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study.
    Chen E, Li Q, Wang H, Yang F, Min L, Yang J.
    Biomed Pharmacother; 2018 Oct 07; 106():1370-1377. PubMed ID: 30119209
    [Abstract] [Full Text] [Related]

  • 40. The inhibition of colorectal cancer growth by the natural product macrocarpal I.
    Qi L, Zhang Y, Zhang W, Wang Y, Han Y, Ding Y.
    Free Radic Biol Med; 2021 Jan 07; 162():383-391. PubMed ID: 33137468
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.